Skip to content

Bioalmanac

Sermorelin

GRF (1-29) · Geref (former brand)

Approved for another indication

Status reviewed 12 Aug 2026

Prohibited in sport

The original GHRH analogue, and the only one here that once held FDA approval, withdrawn for commercial reasons and not for safety.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 9 mg vial, 300 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL9 mg/mL0.033 mL3.33 units30
2 mL4.5 mg/mL0.067 mL6.67 units30
3 mL3 mg/mL0.1 mL10 units30
5 mL1.8 mg/mL0.167 mL16.67 units30

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Commonly prescribed by compounding pharmacies200–500 mcgOnce nightly before bedCommunity practice

When to stop

  • Persistent numbness, tingling or wrist pain, which can indicate fluid-related nerve compression.
  • Noticeable swelling of the hands, feet or face.
  • Unusual thirst, frequent urination or blurred vision, which can indicate raised blood glucose.
  • Any new lump or growth. Investigate rather than watch.
  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.

Formerly FDA approved as Geref, withdrawn from the US market in 2008 for commercial rather than safety reasons. Available through compounding pharmacies under prescription. Material sold as a research chemical is not a compounded prescription product.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/sermorelin

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.